A detailed history of Morgan Stanley transactions in Rx Sight, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,125,651 shares of RXST stock, worth $65.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,125,651
Previous 1,073,062 4.9%
Holding current value
$65.8 Million
Previous $43.3 Million 34.2%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$35.51 - $57.92 $1.87 Million - $3.05 Million
52,589 Added 4.9%
1,125,651 $58.1 Million
Q4 2023

Feb 13, 2024

SELL
$20.91 - $40.9 $2.89 Million - $5.66 Million
-138,342 Reduced 11.42%
1,073,062 $43.3 Million
Q3 2023

Nov 15, 2023

SELL
$27.05 - $33.37 $8 Million - $9.87 Million
-295,671 Reduced 19.62%
1,211,404 $33.8 Million
Q2 2023

Aug 14, 2023

BUY
$16.37 - $28.9 $23.8 Million - $42 Million
1,451,598 Added 2616.58%
1,507,075 $43.4 Million
Q1 2023

May 15, 2023

BUY
$12.58 - $16.68 $402,660 - $533,893
32,008 Added 136.38%
55,477 $925,000
Q4 2022

Feb 14, 2023

SELL
$9.93 - $14.2 $37,088 - $53,037
-3,735 Reduced 13.73%
23,469 $297,000
Q3 2022

Nov 14, 2022

BUY
$11.19 - $15.85 $198,152 - $280,671
17,708 Added 186.48%
27,204 $326,000
Q2 2022

Oct 27, 2022

BUY
$10.61 - $16.66 $63,278 - $99,360
5,964 Added 168.86%
9,496 $134,000
Q2 2022

Aug 15, 2022

BUY
$10.61 - $16.66 $63,278 - $99,360
5,964 Added 168.86%
9,496 $134,000
Q1 2022

Oct 27, 2022

SELL
$8.97 - $14.03 $53,497 - $83,674
-5,964 Reduced 62.81%
3,532 $44,000
Q1 2022

May 13, 2022

BUY
$8.97 - $14.03 $13,589 - $21,255
1,515 Added 75.11%
3,532 $44,000
Q4 2021

Feb 14, 2022

BUY
$9.52 - $13.81 $4,550 - $6,601
478 Added 31.06%
2,017 $23,000
Q3 2021

Nov 15, 2021

BUY
$11.85 - $17.32 $18,237 - $26,655
1,539 New
1,539 $19,000

Others Institutions Holding RXST

About RxSight, Inc.


  • Ticker RXST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 27,638,900
  • Market Cap $1.62B
  • Description
  • RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...
More about RXST
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.